(NASDAQ: CGTX) Cognition Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Cognition Therapeutics's earnings in 2025 is -$27,986,000.On average, 5 Wall Street analysts forecast CGTX's earnings for 2025 to be -$36,316,030, with the lowest CGTX earnings forecast at -$44,119,474, and the highest CGTX earnings forecast at -$31,513,910. On average, 5 Wall Street analysts forecast CGTX's earnings for 2026 to be -$25,211,128, with the lowest CGTX earnings forecast at -$29,412,983, and the highest CGTX earnings forecast at -$19,464,474.
In 2027, CGTX is forecast to generate -$38,717,090 in earnings, with the lowest earnings forecast at -$37,198,772 and the highest earnings forecast at -$39,855,827.